Zacks Research Upgrades Teleflex (NYSE:TFX) to “Strong-Buy”

Teleflex (NYSE:TFX) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Thursday, Zacks reports.

A number of other research analysts also recently commented on the company. Mizuho increased their target price on Teleflex from $140.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Wall Street Zen raised shares of Teleflex from a “sell” rating to a “hold” rating in a research note on Sunday, August 9th. BMO Capital Markets began coverage on shares of Teleflex in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $159.00 price objective for the company. Truist Financial boosted their target price on shares of Teleflex from $143.00 to $150.00 and gave the stock a “hold” rating in a report on Monday, August 10th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $169.00 price target (up from $160.00) on shares of Teleflex in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Teleflex has an average rating of “Moderate Buy” and an average price target of $152.90.

Teleflex Trading Up 2.0%

Shares of Teleflex stock opened at $122.44 on Thursday. Teleflex has a twelve month low of $100.18 and a twelve month high of $145.00. The company has a quick ratio of 2.12, a current ratio of 2.60 and a debt-to-equity ratio of 0.94. The business has a 50-day moving average price of $134.00 and a 200-day moving average price of $128.54. The firm has a market cap of $5.19 billion, a price-to-earnings ratio of -5.26, a PEG ratio of 0.80 and a beta of 0.82.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.48. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%.The company had revenue of $570.33 million during the quarter, compared to analyst estimates of $559.59 million. During the same period in the prior year, the company earned $3.73 earnings per share. The firm’s revenue was up 28.9% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Equities research analysts anticipate that Teleflex will post 7.26 EPS for the current fiscal year.

Institutional Trading of Teleflex

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kelleher Financial Advisors purchased a new position in shares of Teleflex during the second quarter valued at approximately $25,000. Allworth Financial LP bought a new stake in shares of Teleflex during the 2nd quarter worth approximately $44,000. Hantz Financial Services Inc. lifted its stake in shares of Teleflex by 40.5% during the 4th quarter. Hantz Financial Services Inc. now owns 392 shares of the medical technology company’s stock worth $48,000 after acquiring an additional 113 shares during the last quarter. Versant Capital Management Inc boosted its holdings in Teleflex by 573.4% during the 2nd quarter. Versant Capital Management Inc now owns 431 shares of the medical technology company’s stock valued at $55,000 after acquiring an additional 367 shares during the period. Finally, Trust Co. of Vermont bought a new position in Teleflex in the 2nd quarter valued at $57,000. 95.62% of the stock is owned by hedge funds and other institutional investors.

About Teleflex

Teleflex Incorporated is a global medical technology company that develops, manufactures and supplies specialty medical devices for hospitals, clinicians and other health care providers. Its products are designed to support procedures in areas including vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgery and urology.

The company’s portfolio includes Arrow branded vascular access and catheter products, airway management devices, regional anesthesia products, surgical instruments, interventional devices and urological products.